Evaluation of time-dependent response to psoralen plus UVA (PUVA) treatment with topical 8-methoxypsoralen (8-MOP) gel in palmoplantar dermatoses

被引:22
作者
Engin, B [1 ]
Oguz, O [1 ]
机构
[1] Istanbul Univ, Cerrahpasa Med Fac, Dept Dermatol, TR-34303 Istanbul, Turkey
关键词
D O I
10.1111/j.1365-4632.2004.02153.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 [皮肤病与性病学];
摘要
Background Topical psoralen plus UVA (PUVA) is an effective treatment for localized forms of eczema, psoriasis, and palmoplantar pustulosis, which avoids some of the undesirable side-effects of systemic psoralens. Aims In this study, the efficacy of topical PUVA treatment with 8-methoxypsoralen (8-MOP) gel was compared with placebo plus UVA in chronic recurrent palmoplantar dermatoses. Methods Twenty-two patients with palmoplantar disease (11 with psoriasis vulgaris, six with eczema, and five with pustulosis) were enrolled in the study. The study design was a left-right comparison: one hand or foot was treated with 8-MOP 0.01% gel plus UVA, whilst the contralateral hand or foot received placebo and UVA for 6 weeks. Twenty minutes after application of the gel, both sides were exposed to UVA. The treatment regimen was three times a week, and the UVA dose was increased weekly by 20%. Results A comparison of the pre- and post-treatment scores with regard to the severity of the clinical picture and the infiltration of plaques showed a significant decrease (from 7.5 +/- 2.0 to 2.5 +/- 2.1 and from 2.0 +/- 0.7 to 0.3 +/- 0.5, respectively) in the sites treated with 8-MOP gel compared with placebo after 6 weeks. Conclusion The results of the study indicate that at least 18 courses of local PUVA within 6 weeks, with a cumulative dose of 87 J/cm(2), are required to induce a significant decrease in the disease severity and an improvement in the infiltration of plaques due to 8-MOP gel at a concentration of 0.01% when treating chronic recurrent palmoplantar dermatoses.
引用
收藏
页码:337 / 339
页数:3
相关论文
共 11 条
[1]
Christofers E, 1999, Fitzpatrickis Dermatology in General Medicine, V5, P495
[2]
Davis MDP, 1998, MAYO CLIN PROC, V73, P407
[3]
Duthie MS, 1999, BRIT J DERMATOL, V140, P995
[4]
Guidelines for topical PUVA: a report of a workshop of the British Photodermatology Group [J].
Halpern, SM ;
Anstey, AV ;
Dawe, RS ;
Diffey, BL ;
Farr, PM ;
Ferguson, J ;
Hawk, JLM ;
Ibbotson, S ;
McGregor, JM ;
Murphy, GM ;
Thomas, SE ;
Rhodes, LE .
BRITISH JOURNAL OF DERMATOLOGY, 2000, 142 (01) :22-31
[5]
THE EFFICACY OF LOCALIZED PUVA THERAPY FOR CHRONIC HAND AND FOOT DERMATOSES [J].
HAWK, JLM ;
LEGRICE, P .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 1994, 19 (06) :479-482
[6]
JANSEN CT, 1981, ACTA DERM-VENEREOL, V61, P354
[7]
A CONTROLLED TRIAL OF PHOTOCHEMOTHERAPY FOR PERSISTENT PALMOPLANTAR PUSTULOSIS [J].
MURRAY, D ;
CORBETT, MF ;
WARIN, AP .
BRITISH JOURNAL OF DERMATOLOGY, 1980, 102 (06) :659-663
[8]
Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA) [J].
Stern, RS ;
Nichols, KT ;
Vakeva, LH .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (15) :1041-1045
[9]
STERN RS, 1994, CANCER-AM CANCER SOC, V73, P2759, DOI 10.1002/1097-0142(19940601)73:11<2759::AID-CNCR2820731118>3.0.CO
[10]
2-C